THE IMPACT OF NON-MEDICAL SWITCHING FROM ORIGINATOR TO BIOSIMILAR INFLIXIMAB VS CONTINUING ON ORIGINATOR IN INFLAMMATORY BOWEL DISEASE: RESULTS OF PROJECT NORTH

Per Martin Hellström  1     Eric Gemmen  2     Heather Ward     Hyewon Koo  3     Freddy Faccin  4     Zhenyi Xue     Petter Malmborg  5    
1 Uppsala University, Uppsala, Sweden
2 IQVIA Real World Solutions, Cambridge, United States
3 IQVIA Solutions AB, Solna, Sweden
4 AbbVie Inc, North Chicago, United States
5 Karolinska Institutet, Stockholm, Sweden

Session
IBD (Posters)

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing